Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03543566 · ClinicalTrials.gov registry record
Bladder Antimuscarinic Medication and Accidental Bowel Leakage
A clinical trial of Fecal Incontinence and Urinary Incontinence, Urge, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 32
- Enrollment target
- 1
- Study location
NCT03543566 is a study of Fecal Incontinence and Urinary Incontinence, Urge that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 32 participants, below the 334-participant average among 22 other Fecal Incontinence trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03543566, a study of Fecal Incontinence and Urinary Incontinence, Urge, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational research study will examine whether a medication known as darifenacin (Enablex ®) used for urgency urinary incontinence (UUI) also helps to improve fecal incontinence symptoms. Darifenacin is FDA approved for UUI, but is not FDA approved for fecal incontinence or specifically for dual incontinence (treatment of urinary incontinence and fecal incontinence at the same time). If participants are eligible for this study, they will have had symptoms of bothersome urgency urinary incontinence and fecal incontinence, and have decided to try medication for urgency urinary incontinence. Darifenacin (Enablex ®) is an oral medication which relaxes the bladder muscle to help prevent urgency urinary leakage. It is commonly used to treat overactive bladder and urgency urinary leakage. There is some evidence that this medication may also help with fecal incontinence by slowing the gut and preventing loose stools. Investigators are planning to enroll approximately 30 patients who have both UUI and fecal incontinence and who choose medical treatment as a part of their standard care.
Conditions Studied
Study Locations (1)
Alabama
- UAB Kirklin Clinic - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2019-01-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03543566
The ClinicalTrials.gov registry entry for NCT03543566 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 334-participant average among 22 other Fecal Incontinence trials with a reported enrollment target (90% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Fecal Incontinence appearing as the primary indexed condition, and to 0 interventions.
NCT03543566 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT03543566 about?
NCT03543566 is a clinical study titled "Bladder Antimuscarinic Medication and Accidental Bowel Leakage". This observational research study will examine whether a medication known as darifenacin (Enablex ®) used for urgency urinary incontinence (UUI) also helps to improve fecal incontinence symptoms. Darifenacin is FDA approved for UUI, but is not FDA approved for fecal incontinence or specifically for ...
What is the current status of trial NCT03543566?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2018-05-21. Estimated completion is 2019-01-18.
What conditions does trial NCT03543566 study?
This clinical trial studies the following conditions: Fecal Incontinence, Urinary Incontinence, Urge.
Who is sponsoring clinical trial NCT03543566?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03543566 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fecal Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Indiana University Gastrointestinal Motility Diagnosis Registry
RECRUITING
-
Mechanisms of Improving Fecal Continence Muscles Motor Function
RECRUITING · NA
-
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
RECRUITING · NA
-
Autologous Muscle Fiber Fragment Injections
RECRUITING · NA
-
Pelvic Health Electrically Evoked Recording (PEER) 2 Study
RECRUITING · NA
-
Home Biofeedback Therapy for Dyssynergic Defecation, Fecal Incontinence and Urinary Incontinence
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.